Leadership

Isabelle Lousada has been the driving force behind ARC, building successful collaborations and programs across the sectors to advance the science and understanding of the amyloidosis diseases.

Isabelle was diagnosed with AL amyloidosis, and was one of the first patients to successfully undergo a stem cell transplant. For the past twenty years she has been committed to empowering other patients while serving on several boards and committees, speaking at leadership meetings and key events to encourage research, increase access, and support the critical and unmet needs of amyloidosis patients.

Prior to joining ARC, Eric spent twenty years as the chief executive of Myeloma UK, an internationally renowned non-profit. There, he committed more funding than any other organization to amyloidosis research. His expertise, keen interest in ensuring patients have access to treatment and visionary work will catalyze the ARC’s programs to accelerate drug development.

Kristen has over ten years of clinical operations experience within the pharmaceutical industry. She has a wealth of experience in managing complex global clinical trials for novel treatments of rare diseases. Kristen is building and overseeing the ARC’s clinical research program and manages a prioritized portfolio of vital research.